Blog

Ciara C. O’Sullivan of Mayo Clinic, leads the Alliance A011801 trial – Alliance for Clinical Trials in Oncology

Photo from Alliance for Clinical Trials in Oncology/LinkedIn

May 17, 2024, 13:16

Ciara C. O’Sullivan of Mayo Clinic, leads the Alliance A011801 trial – Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology shared on LinkedIn:

“For Trial Tuesday, Ciara C. O’Sullivan, MB, BCh, of Mayo Clinic, leads the Alliance A011801 (CompassHER2 RD) trial to see how targeted therapy linked to a chemotherapy drug works to prevent breast cancer from returning in patients with high-risk HER2+ breast cancer. To learn more about the CompassHER2 RD trial.”

Further Reading.
Source: Alliance for Clinical Trials in Oncology/LinkedIn

Alliance A011801 Alliance for Clinical Trials in Oncology cancer chemotherapy Ciara C. O'Sullivan CompassHER2 RD trial HER2+ breast cancer Mayo Clinic OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage